艾叶提取物经PI3K/MAPK通路诱导吉西他滨耐药肺癌细胞凋亡
本研究以人肺癌CL1-0亲本细胞及吉西他滨耐药CL1-0-GR细胞为对象,观察艾叶提取物(AAE)的抗肿瘤作用及机制。AAE可降低两种细胞活力、诱导凋亡,伴线粒体膜去极化与ROS升高,并抑制侵袭、迁移、EMT及球体形成;凋亡经PI3K/AKT与MAPK通路调控,AAE与化疗药联用可增强肿瘤球体缩小。
要点
- AAE对亲本及吉西他滨耐药肺癌细胞均降低活力并诱导凋亡。
- AAE抗肿瘤作用涉及ROS升高、线粒体膜去极化及PI3K/AKT、MAPK通路。
- AAE与化疗药联用可增强肿瘤球体缩小,提示辅助潜力。
核心结论
- 艾叶提取物可抑制亲本与吉西他滨耐药肺癌细胞,机制涉及诱导ROS、线粒体膜去极化与凋亡,并减少EMT。
- 艾叶提取物可能作为化疗辅助药增强化疗药疗效。
研究设计与样本
- 体外细胞实验,使用人肺癌CL1-0亲本细胞与吉西他滨耐药CL1-0-GR细胞。
- 采用MTT、克隆形成与球体形成实验评估细胞活力。
主要发现
- AAE显著降低CL1-0与CL1-0-GR细胞活力并诱导凋亡。
- AAE处理后伴线粒体膜去极化与ROS水平升高。
- AAE抑制两种细胞的侵袭、迁移、EMT、克隆形成与球体形成。
- AAE与商业化化疗药联用可增强肿瘤球体缩小。
关键数值与推荐
- AAE诱导的凋亡经PI3K/AKT与MAPK信号通路调控。
临床怎么用
- 提示艾叶提取物可能作为化疗辅助用药,但需进一步体内与临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Artemisia argyi H. Lév. & Vaniot (Asteraceae), also called "Chinese mugwort", is frequently used as a herbal medicine in China, Japan, Korea, and eastern parts of Russia. It is known as "ai ye" in China and "Gaiyou" in Japan. In ancient China, the buds and leaves of A. argyi were commonly consumed before and after Tomb-sweeping Day. It is used to treat malaria, hepatitis, cancer, inflammatory diseases, asthma, irregular menstrual cycle, sinusitis, and pathologic conditions of the kidney and liver. Although A. argyi extract (AAE) has shown anti-tumor activity against various cancers, the therapeutic effect and molecular mechanism of AAE remains to be further studied in lung cancer. AIM OF THE STUDY: This study aimed to demonstrate the anti-tumor effect of AAE and its associated biological mechanisms in CL1-0 parent and gemcitabine-resistant (CL1-0-GR) lung cancer cells. EXPERIMENTAL PROCEDURE: Human lung cancer cells CL1-0 and CL1-0-GR cells were treated with AAE. Cell viability was assessed using the MTT, colony, and spheroid formation assays. Migration, invasion, and immunofluorescence staining were used to determine the extent of epithelial- mesenchymal transition (EMT). JC-1 and MitoSOX fluorescent assays were performed to investigate the effect of AAE on mitochondria. Apoptosis was detected using the TUNEL assay and flow cytometry with Annexin V staining. RESULT: We found that A. argyi significantly decreased cell viability and induced apoptosis, accompanied by mitochondrial membrane depolarization and increased ROS levels in both parent cells (CL1-0) and gemcitabine-resistant lung cancer cells (CL1-0-GR). AAE-induced apoptosis is regulated via the PI3K/AKT and MAPK signaling pathways. It also prevents CL1-0 and CL1-0-GR cancer cell invasion, migration, EMT, colony formation, and spheroid formation. In addition, AAE acts cooperative with commercial chemotherapy drugs to enhance tumor spheroid shrinkage. CONCLUSION: Our study provides the first evidence that A. argyi treatment suppresses both parent and gemcitabine-resistant lung cancer cells by inducing ROS, mitochondrial membrane depolarization, and apoptosis, and reducing EMT. Our finding provides insights into the anti-cancer activity of A. argyi and suggests that A. argyi may serve as a chemotherapy adjuvant that potentiates the efficacy of chemotherapeutic agents.
引用
- Su SH, Sundhar N, Kuo WW, et al. Artemisia argyi extract induces apoptosis in human gemcitabine-resistant lung cancer cells via the PI3K/MAPK signaling pathway. J Ethnopharmacol. 2022. PMID: 36075273. doi:10.1016/j.jep.2022.115658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。